MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to qualigen...
-$2,905,615
Net loss
-$2,037,819
Deemed dividend
arising from preferred...
$867,796
Net loss from
continuing operations
-$2,037,819
Loss before (benefit
from) provision for...
-$2,037,819
Loss from operations
-$1,429,684
Total other expense
(income), net
-$608,135
Interest income
$193,819
Total expenses
$1,429,684
Interest expense
$455,941
Loss on change in fair
value of convertible...
-$197,667
Credit loss expense -
short-term note receivable
-$567,000
Loss (gain) on change
in fair value of...
-$148,346
General and
administrative
$1,891,108
Research and development
$105,576
Back
Back
Income Statement
source: myfinsight.com
Qualigen Therapeutics, Inc. (QLGN)
Qualigen Therapeutics, Inc. (QLGN)